Commonly used in the treatment of bipolar disorder and other mood disorders, lithium could prove promising for inhibiting HIV ...

India, Feb. 1 -- A first-of-its-kind facility that blends Ayurveda, yoga and modern therapies, the PRAYAS centre at the ...

Professor Jaewon Ko’s research team at DGIST, in collaboration with international researchers, identified that the loss of function of the MDGA2 gene induces severe developmental and epileptic encepha ...

Let's see what this stock has announced on Thursday. The post ASX 200 healthcare stock sinks 9% on FDA update appeared first ...

Attention-deficit/hyperactivity disorder is one of the most researched neurodevelopmental conditions, yet 5 ADHD myths people ...

The crisis facing rare disease and disability families in Connecticut is caused by systemic underinvestment, administrative barriers, and policy choices.

Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful ...

A first-of-its-kind facility that blends Ayurveda, yoga and modern therapies, the PRAYAS centre at the All India Institute of Ayurveda in Goa is emerging as a ray of hope for children with ...

Congenital stationary night blindness (CSNB) is caused by mutations in a specific calcium channel. A comprehensive proteomic study by researchers at the University of Innsbruck now reveals how these ...

Sanofi’s LEAP2MONO phase 3 study of venglustat to treat type 3 Gaucher disease meets all primary endpoints: Paris Tuesday, February 3, 2026, 13:00 Hrs [IST] Positive results fro ...

Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful effic ...

PRAYAS at AIIA Goa blends Ayurveda, yoga and modern therapies to improve life for children with cerebral palsy, autism, ADHD and neuro disorders.